21% activation probability · Early buildup from the live window
Breadth0%
Bridge20 / Fragile
Decision Frame
Why it matters, what confirms, what breaks
Why It Matters
Live thesis
This cluster focuses on companies developing specialty plasma-derived biologics for healthcare applications, particularly in treating immune deficiencies and infectious diseases.
Decision context
Live breadth at 0% with ADMA leading
Best bridge
EQR to DX-Y.NYB is the strongest transmission path right now.
What Confirms
EQR -> DX-Y.NYB
weak bridge transmission across the current structure.
ADMA
ADMA is the current leadership name for Plasma Biologics, carrying the highest structural influence in the live cluster.
What Breaks
Leader dependence
ADMA still carries the highest influence in the live cluster.
Breadth compression
Watch for participation slipping below 30%.
Bridge failure
1 cross-asset bridge(s) are available as confirmation checks.